Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025)
Editas Medicine's (EDIT) quarterly Return on Capital Employed came in at 137.71% in Q3 2025, down 5720.0% year-on-year from 2.45% in Q3 2024, and up 1.76% on a QoQ basis from 140.18% in Q2 2025.
Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 10 years of Return on Capital Employed data on file, last reported at 137.71% in Q3 2025.
- On a quarterly basis, Return on Capital Employed fell 5720.0% year-over-year to 137.71% in Q3 2025; TTM through Sep 2025 was 137.71%, a 5720.0% decrease from a year earlier, with the FY2024 full-year figure at 73.19%, down 3505.0% from the prior year.
- Return on Capital Employed for Q3 2025 stood at 137.71%, up from 140.18% in the prior quarter.
- Over the last five years, Return on Capital Employed for EDIT reached as high as 23.69% in Q1 2021 and fell as low as 140.18% in Q2 2025.
- Historically, Return on Capital Employed has averaged 59.13% across 5 years, with a median of 45.93% in 2024.
- Across the five-year window, Return on Capital Employed jumped 1361 bps in 2021 and sank 7721 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 29.7% in 2021, then tumbled by 64 bps to 48.85% in 2022, then grew by 21 bps to 38.57% in 2023, then plunged by 153 bps to 97.59% in 2024, then tumbled by 41 bps to 137.71% in 2025.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 137.71% in Q3 2025, 140.18% in Q2 2025, and 113.43% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -137.71% |
| Jun 30, 2025 | -140.18% |
| Mar 31, 2025 | -113.43% |
| Dec 31, 2024 | -97.59% |
| Sep 30, 2024 | -80.51% |
| Jun 30, 2024 | -62.97% |
| Mar 31, 2024 | -45.93% |
| Dec 31, 2023 | -38.57% |
| Sep 30, 2023 | -44.90% |
| Jun 30, 2023 | -48.16% |
| Mar 31, 2023 | -52.35% |
| Dec 31, 2022 | -48.85% |
| Sep 30, 2022 | -39.74% |
| Jun 30, 2022 | -32.86% |
| Mar 31, 2022 | -30.47% |
| Dec 31, 2021 | -29.70% |
| Sep 30, 2021 | -31.71% |
| Jun 30, 2021 | -24.10% |
| Mar 31, 2021 | -23.69% |
| Dec 31, 2020 | -25.60% |